Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paliperidone

FDA-approved product (tablet, extended release, oral), marketed as Invega, Paliperidone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Paliperidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paliperidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paliperidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders

    NCT01742390 · start 2013-02

    Registered record
    Registry ID
    NCT01742390
    Conditions
    Sexual Dysfunction; Hyperprolactinemia
    Interventions
    Aripiprazole; risperidone or paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-02
    Completion
    2014-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSexual Dysfunction; Hyperprolactinemia
    InterventionAripiprazole; risperidone or paliperidone
    PhasePhase 4
    Registry statusUnknown

  • Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

    NCT01515423 · start 2012-05

    Registered record
    Registry ID
    NCT01515423
    Conditions
    Schizophrenia
    Interventions
    PP3M 175 mg eq.; PP3M 263 mg eq.; PP3M 350 mg eq.; PP3M 525 mg eq.; Placebo (20% Intralipid); PP1M 50 mg eq.; PP1M 75 mg eq.; PP1M 100 mg eq.; PP1M 150 mg eq.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2015-03
    Enrolment
    1,429

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPP3M 175 mg eq.; PP3M 263 mg eq.; PP3M 350 mg eq.; PP3M 525 mg eq. +5 more
    PhasePhase 3
    Registry statusCompleted

  • A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

    NCT01529515 · start 2012-05

    Registered record
    Registry ID
    NCT01529515
    Conditions
    Schizophrenia
    Interventions
    PP3M 175 mg eq.; PP3M 263 mg eq.; PP3M 350 mg eq.; PP3M 525 mg eq.; Placebo (20% Intralipid emulsion)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-04
    Enrolment
    509

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPP3M 175 mg eq.; PP3M 263 mg eq.; PP3M 350 mg eq.; PP3M 525 mg eq. +1 more
    PhasePhase 3
    Registry statusCompleted

  • A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate

    NCT01682161 · start 2012-01

    Registered record
    Registry ID
    NCT01682161
    Conditions
    Schizophrenia
    Interventions
    Paliperidone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-09
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone palmitate
    PhasePhase 4
    Registry statusCompleted

  • The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

    NCT04076371 · start 2012-01

    Registered record
    Registry ID
    NCT04076371
    Conditions
    Schizophrenia
    Interventions
    olanzapine-sertraline combination; only olanzapine; risperidone-sertraline combination; only risperidone; paliperidone-sertraline combination; only paliperidone; ziprasidone-sertraline combination; only ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-01
    Completion
    2018-12
    Enrolment
    1,640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionolanzapine-sertraline combination; only olanzapine; risperidone-sertraline combination; only risperidone +4 more
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients

    NCT01819818 · start 2011-05-23

    Registered record
    Registry ID
    NCT01819818
    Conditions
    Schizophrenia
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-05-23
    Completion
    2019-11-29
    Enrolment
    3,267

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionNo intervention
    PhaseNot recorded
    Registry statusCompleted

  • A Comparison of Long-acting Injectable Medications for Schizophrenia

    NCT01136772 · start 2011-03

    Registered record
    Registry ID
    NCT01136772
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    haloperidol decanoate; paliperidone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2016-07
    Enrolment
    311

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    Interventionhaloperidol decanoate; paliperidone palmitate
    PhasePhase 4
    Registry statusCompleted

  • A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia

    NCT01258920 · start 2010-10

    Registered record
    Registry ID
    NCT01258920
    Conditions
    Schizophrenia
    Interventions
    Paliperidone palmitate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10
    Completion
    2012-11
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone palmitate
    PhasePhase 3
    Registry statusCompleted

  • Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics

    NCT01081769 · start 2010-02

    Registered record
    Registry ID
    NCT01081769
    Conditions
    Schizophrenia
    Interventions
    paliperidone palmitate injection; oral antipsychotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-02
    Completion
    2013-02
    Enrolment
    769

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone palmitate injection; oral antipsychotics
    PhasePhase 3
    Registry statusCompleted

  • Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

    NCT00937261 · start 2009-07

    Registered record
    Registry ID
    NCT00937261
    Conditions
    Schizophrenia
    Interventions
    Risperidone; Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-07
    Completion
    2011-01
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone; Paliperidone
    PhasePhase 4
    Registry statusUnknown

  • A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men

    NCT01060228 · start 2009-01

    Registered record
    Registry ID
    NCT01060228
    Conditions
    Schizophrenia; Epilepsy
    Interventions
    paliperidone ER; divalproex sodium ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Epilepsy
    Interventionpaliperidone ER; divalproex sodium ER
    PhasePhase 1
    Registry statusCompleted

  • Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia

    NCT01279213 · start 2009-01

    Registered record
    Registry ID
    NCT01279213
    Conditions
    Schizophrenia; Schizophrenic Disorders; Psychotic Disorder
    Interventions
    paliperidone clozapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-12
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophrenic Disorders; Psychotic Disorder
    Interventionpaliperidone clozapine
    PhasePhase 4
    Registry statusCompleted

  • Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

    NCT00827840 · start 2008-11

    Registered record
    Registry ID
    NCT00827840
    Conditions
    Schizophrenia
    Interventions
    Paliperidone ER; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-11
    Completion
    2011-02
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone ER; Risperidone
    PhasePhase 4
    Registry statusCompleted

  • Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)

    NCT00766064 · start 2008-09

    Registered record
    Registry ID
    NCT00766064
    Conditions
    Posttraumatic Stress Disorder
    Interventions
    Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-09
    Completion
    2009-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorder
    InterventionPaliperidone
    PhasePhase 4
    Registry statusWithdrawn

  • PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia

    NCT00761189 · start 2008-02

    Registered record
    Registry ID
    NCT00761189
    Conditions
    Schizophrenia
    Interventions
    Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-02
    Completion
    2010-07
    Enrolment
    491

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone
    PhasePhase 4
    Registry statusCompleted